Axsome Therapeutics Inc Enters into Exclusive License Agreement with Pfizer Inc Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to the Axsome Therapeutics conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
And I would now like to turn the conference over to your host today, Mr. Mark Jacobson, Senior Vice President of Operations at Axsome Therapeutics. Please go ahead, sir.
Thank you, operator. Good morning, everyone, and thank you for joining us on today's conference call. A press release announcing that Axsome has entered into an exclusive license agreement with Pfizer crossed the wire a short time ago and is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements, and these statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and nonclinical plans, our plans to present or report additional data, the anticipated conduct and the source of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |